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Abstract
Introduction: Hydrogen sulfide (H2S) has been shown to improve survival in rodent models of lethal hemorrhage.
Conversely, other authors have reported that inhibition of endogenous H2S production improves hemodynamics
and reduces organ injury after hemorrhagic shock. Since all of these data originate from unresuscitated models
and/or the use of a pre-treatment design, we therefore tested the hypothesis that the H2S donor, sodium
hydrosulfide (NaHS), may improve hemodynamics in resuscitated hemorrhagic shock and attenuate oxidative and
nitrosative stresses.
Methods: Thirty-two rats were mechanically ventilated and instrumented to measure mean arterial pressure (MAP)
and carotid blood flow (CBF). Animals were bled during 60 minutes in order to maintain MAP at 40 ± 2 mm Hg.
Ten minutes prior to retransfusion of shed blood, rats randomly received either an intravenous bolus of NaHS (0.2
mg/kg) or vehicle (0.9% NaCl). At the end of the experiment (T = 300 minutes), blood, aorta and heart were
harvested for Western blot (inductible Nitric Oxyde Synthase (iNOS), Nuclear factor-B (NF-B), phosphorylated
Inhibitor B (P-IB), Inter-Cellular Adhesion Molecule (I-CAM), Heme oxygenase 1(HO-1), Heme oxygenase 2(HO-2),
as well as nuclear respiratory factor 2 (Nrf2)). Nitric oxide (NO) and superoxide anion (O2
-) were also measured by
electron paramagnetic resonance.
Results: At the end of the experiment, control rats exhibited a decrease in MAP which was attenuated by NaHS
(65 ± 32 versus 101 ± 17 mmHg, P < 0.05). CBF was better maintained in NaHS-treated rats (1.9 ± 1.6 versus 4.4 ±
1.9 ml/minute P < 0.05). NaHS significantly limited shock-induced metabolic acidosis. NaHS also prevented iNOS
expression and NO production in the heart and aorta while significantly reducing NF-kB, P-IB and I-CAM in the
aorta. Compared to the control group, NaHS significantly increased Nrf2, HO-1 and HO-2 and limited O2
- release in
both aorta and heart (P < 0.05).
Conclusions: NaHS is protective against the effects of ischemia reperfusion induced by controlled hemorrhage in
rats. NaHS also improves hemodynamics in the early resuscitation phase after hemorrhagic shock, most likely as a
result of attenuated oxidative stress. The use of NaHS hence appears promising in limiting the consequences of
ischemia reperfusion (IR).
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Introduction
Hemorrhagic shock (HS) is a life-threatening complica-
tion in both trauma patients and in the operating room
[1,2]. The pathophysiology of HS is complex, especially
during the reperfusion phase [3]. During HS, the state
of vasoconstriction turns into vasodilatory shock.
According to Landry et al. [4], this phenomenon is
related to tissue hypoxia as well as to a proinflammatory
immune response [4]. In addition, during the reperfu-
sion phase, cellular injuries induced by ischemia are
enhanced, and are associated with excessive production
of radical oxygen species (ROS), leading to a further sys-
temic inflammatory response [5].
Hydrogen sulfide (H2S), is known as an environmental
toxic gas [6], but has also recently been recognized as a
gasotransmitter [7], similar to nitric oxide (NO) and car-
bon monoxide (CO). H2S is endogenously synthesized
[8] and may play a crucial role in critical care according
to the recent review of Wagner et al. in 2009 [9].
Depending on the selected models, H2S has been
reported to exhibit pro- and anti-inflammatory proper-
ties and to display opposite effects in various shock con-
ditions [10-13]. H2S has also been reported to induce
direct inhibition of endothelial nitric oxide synthase
(eNOS) [14]. However, this effect was linked to the con-
centration of H2S, whereby H2S caused contraction at
low doses and relaxation at high doses in both rat and
mouse aorta precontracted by phenylephrine [14]. This
dual effect was related, at low dosage, to the inhibition
of the conversion of citrulline into arginine by eNOS
(contraction) and at high dosage by activation of K+ATP
channels or due to NO quenching [15]. Blackstone et al.
[10,11] recently suggested that inhalation of H2S
induced a “suspended animation-like” state which pro-
tected animals from lethal hypoxia. Furthermore, Morri-
son et al. [16] demonstrated that pre-treatment with
inhaled or intravenous (i.v.) H2S prevented death and
lethal hypoxia in rats subjected to controlled but unre-
suscitated hemorrhage.
Conversely, Mok et al. [17] reported the hemody-
namic effects of the inhibition of H2S synthesis, along
with a rapid restoration in mean arterial pressure
(MAP) and heart rate (HR), in a model of unresuscitated
hemorrhage in rats.
As the vascular effects of H2S are still a matter of
debate, and since all of these data originated from unre-
suscitated hemorrhage, we therefore tested the hypoth-
esis that the H2S donor sodium hydrosulfide (NaHS),
infused before retransfusion in a model of a controlled
hemorrhagic rat, may improve hemodynamics and
attenuate oxidative and nitrosative stresses, as well as
the inflammatory response during reperfusion. Since the
role of the cardiovascular system during shock becomes
critical, we therefore focused on the inflammatory
response as well as on the oxidative and nitrosative
stresses in the heart and aorta.
Materials and methods
The animal protocol was approved by the regional ani-
mal ethics committee (CREEA-Nantes, France). The
experiments were performed in compliance with the
European legislation on the use of laboratory animals.
Animals
Adult male Wistar rats, weighing 325 ± 15 g, were
housed with 12-hour light/dark cycles in the animal
facility of the University of Angers (France).
Surgical procedure
Animals were anesthetized with intraperitoneal pento-
barbital (50 mg/kg of body weight) and placed on a
homeothermic blanket system in order to maintain rec-
tal temperature between 36.8°C and 37.8°C throughout
the experiment. After local anesthesia with lidocaine 1%
(Lidocaine® 1% AstraZeneca, Reuil-Malmaison, France),
a tracheotomy was performed. Animals were mechani-
cally ventilated (Harvard Rodent 683 ventilator, Harvard
Instruments, South Natick, MA, USA) and oxygen was
added in order to maintain PaO2 above 100 mmHg. The
left carotid artery was exposed, and a 2.0 mm transit-
time ultrasound flow probe (Transonic Systems Inc.,
Ithaca, NY, USA) was attached to allow continuous
measurement of blood flow (CBF).
After local anesthesia, the femoral artery was canulated
both to measure MAP and HR and for the induction of
hemorrhagic shock. The homolateral femoral vein was
canulated for retransfusion of shed blood, for fluid main-
tenance and for bolus infusion (either vehicle or NaHS).
Induction of hemorrhagic shock and protocol design
After a 20-minute stabilization period, controlled
hemorrhage [18] was induced by withdrawing approxi-
mately 9 ml of blood collected in a heparinized syringe
(200 UI) within 10 minutes until MAP decreased to
40 ± 2 mmHg. This state of controlled hemorrhage was
maintained during 60 minutes by further blood withdra-
wal or reinfusion of shed blood. Ten minutes prior to
retransfusion time, rats were randomly allocated to
receive either NaHS (single i.v. bolus 0.2 mg/kg body
weight) or control (vehicle 0.9% NaCl), and designated
as HS-NaHS (n = 11) and HS-saline (n = 11) respec-
tively. After 60 minutes of shock, shed blood was
retransfused within 10 minutes. Animals were continu-
ously monitored for HR, MAP and CBF during 300
minutes. At the end of the experiment, the rats were
sacrificed and blood samples were collected for
Ganster et al. Critical Care 2010, 14:R165
http://ccforum.com/content/14/5/R165
Page 2 of 11
measurement of arterial lactate levels. Aorta and hearts
were harvested and maintained in liquid nitrogen for
further in vitro analyses (Western blotting, superoxide
anion and NO production) (Figure 1).
Two additional groups of rats were managed in the
same manner as the other animals but were not bled.
One group (control-NaHS, n = 5) received a single
bolus of NaHS (0.2 mg/kg body weight) while the other
group received the vehicle (0.9% NaCl 0.2 mg/kg body
weight) (control-saline n = 5) in order to assess the
hemodynamic effects of NaHS in normal rats.
Maintenance of fluid was performed with a perfusion
of 1.2 ml per hour of 0.9% NaCl in all groups.
Hydrogen sulfide donor preparation
The dehydrated NaHS powder (sodium hydrogen sul-
fide, anhydrous, 2 g, Alpha Aesar GmbH & Co, UK)
was dissolved in isotonic saline under argon gas bub-
bling, until a concentration of 40 mM was achieved.
Intravenous (i.v.) administration was preferred to the
inhaled form of H2S, as it represented an easier route
whilst avoiding side effects such as airway irritation. In
accordance with pilot experimentations in our labora-
tory and a previous study [19], a single intravenous
bolus of NaHS (0.2 mg/kg) was infused.
Monitoring and measurements
Arterial blood gases were controlled after the stabiliza-
tion period in order to adjust mechanical ventilation.
Blood gases, acid-base status and blood glucose were
recorded at baseline (t = 0 minute), at the end of
retransfusion (t = 70 minutes) and at the end of the
experiment (t = 300 minutes). MAP, HR, CBF and tem-
perature were recorded during the stabilization period
(baseline) and every 10 minutes during the observation
period.
In vitro measurements
Determination by electron paramagnetic resonance (EPR)
NO spin trapping
Aorta and heart samples were incubated for 30 minutes
in Krebs-Hepes buffer containing: BSA (20.5 g/L), CaCl2
(3 mM) and L-Arginine (0.8 mM). N, N D-Ethyldithio-
carbamate and Fe3+ citrate complex (FeDETC) (3.6 mg)
and FeSO4.7H2O (2.25 mg) were separately dissolved
under N2 gas bubbling in 10 ml volumes of ice-cold
Krebs-Hepes buffer. These compounds were rapidly
mixed to obtain a pale yellow-brown opalescent colloid
Fe(DETC)2 solution (0.4 mM), which was used immedi-
ately. The colloid Fe(DETC)2 solution was added to the
organs and incubated for 45 minutes at 37°C. There-
after, the organs were snap frozen in plastic tubes using
liquid N2. NO measurement was performed on a table-
top x-band spectrometer Miniscope (Magnettech,
MS200, Berlin, Germany). Recordings were performed
at 77°K, using a Dewar flask. Instrument settings were:
microwave power, 10 mW; amplitude modulation,
1 mT; modulation frequency, 100 kHz; sweep time, 60 s
Figure 1 Design of the protocol (in case of hemorrhagic shock).
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and number of scans, 5. Levels of NO were expressed as




Aorta and heart samples were allowed to equilibrate in
deferoxamine-chelated Krebs-Hepes solution containing
1 hydroxy-3methoxycarbonyl 2,2,5,5-tetramethylpyrroli-
din (CMH, Noxygen, Germany) (500 μM), deferoxamine
(25 μM) and DETC (5 μM) under constant temperature
(37°C) for one hour. The reaction was stopped by placing
the samples in ice, subsequently frozen in liquid N2 and
analyzed in a Dewar flask by EPR spectroscopy (Magnet-
tech, MS200, Berlin, Germany). The instrument settings
were as follows: temperature, 77° K; microwave power, 1
mW; amplitude modulation, 0.5 mT; sweep time, 60 s;
field sweep, 60 G. Values were expressed in signal ampli-
tude/mg weight of dried tissue (Amplitude/Wd).
Western blotting
Aorta and heart samples were homogenized in lysis buf-
fer (0.5 M Tris-HCl, 1.86 g/ml EDTA, 1 M NaCl, 0.001
g/ml Digitonin, 4 U/ml Aprotinin, 2 μM Leupeptin,
100 μM phenylmethylsulfonyl fluoride (PMSF)). Proteins
(20 μg) were separated on 10% SDS-PAGE and trans-
ferred onto nitrocellulose membranes. Blots were
probed by an over-night incubation (4°C) with a mouse
anti-inducible NOS (iNOS) antibody (BD Biosciences,
San Jose, CA, USA), a polyclonal rabbit nuclear factor
NF-kB p65 antibody (Abcam, Cambridge, UK), a mouse
anti-human phosphorylated (ser32/36)-IkB alpha
(P-IkBa) antibody (US Biologica, Swampscott, Massa-
chusetts, USA), an anti-rat I-CAM/CD54 antibody
(R&D Systems), a goat COX-1(M-20) antibody (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), a goat
COX-2 antibody (Santa Cruz Biotechnology), a rabbit
polyclonal nuclear respiratory factor Nrf2 (C-20) anti-
body (Santa Cruz Biotechnology), a rabbit anti-heme-
oxygenase-1 (HO-1) polyclonal antibody (Stressgen
Bioreagents, San Diego California, USA) or a rabbit
anti-heme-oxygenase-2 (HO-2) polyclonal antibody
(Stressgen Bioreagents, San Diego California, USA).
Membranes were washed and incubated for one hour at
room temperature with a secondary anti-mouse, anti-
rabbit or anti-goat peroxidase-conjugated IgG (Promega,
Madison, WI, USA).
Blots were visualized using an enhanced chemilumines-
cence system (ECL Plus; Amersham, Buckinghamshire,
UK), after which the membranes were probed again with
a polyclonal rabbit anti-b-actin antibody (Sigma-Aldrich,
Saint Quentin Fallavier, France) for densitometric quanti-
fication and normalization to b-actin expression.
Data analysis
For repeated measurements, one-way analysis of var-
iance was used to evaluate within-group differences. Dif-
ference between groups was tested using a two-way
analysis of variance (repeated time measurements and
treatments as independent variables). When the relevant
F values were significant at the 5% level, further pairwise
comparisons were performed using the Dunnett’s test
for the effect of time and with Bonferroni’s correction
for the effects of treatment at specific times. The Mann-
Whitney test was used for inter-group comparisons for
Western blotting, NO and O2
- signal measurements. All
values are presented as mean ± SD for n experiments (n
representing the number of animals). All statistics were
performed with the Statview software (version 5.0; SAS
Institute, Cary, NC, USA). A P-value < 0.05 was consid-
ered statistically significant.
Results
The hydrogen sulfide donor, NaHS, prevents ischemia-
reperfusion (I/R)-induced hemodynamic dysfunction
There was no significant difference in hemodynamic
parameters at baseline (Table 1, Figure 2). Both hemor-
rhage groups were similarly bled (9.2 ± 1.8 mL versus
9.2 ± 1.6 mL for HS-saline and HS-NaHS respectively).
While HR was unaffected, MAP and CBF remained sig-
nificantly decreased after controlled HS despite retrans-
fusion of shed blood, although this effect was
significantly (P < 0.05) attenuated in HS-NaHS-treated
animals (Figure 2). All HS-NaHS-treated animals sur-
vived, whereas 5 animals out of 11 died in the HS-saline
group within five hours of experimentation from refrac-
tory hypotension. The mean survival time in the HS-sal-
ine group was 230 ± 89 minutes. Arterial pH and base
excess were similar at baseline.
Compared to the control group, NaHS significantly
limited the decrease in pH during the reperfusion period
(P < 0.05) (Table 1). In both control-saline and control-
NaHS groups, hemodynamics remained unaltered
(MAP, CBF and HR), as was arterial pH. Hence, EPR
and Western blot analysis were not performed in these
groups.
NaHS prevents I/R-dependent iNOS expression and NO
overproduction in cardiovascular tissues
Compared to the HS-saline group, NaHS treatment in
hemorrhagic rats prevented I/R-induced NO overpro-
duction in the aorta and heart (P < 0.05) (Figure 3a, c).
In agreement with these data, a decreased iNOS protein
concentration was found in both aorta and heart in the
HS-NaHS group (Figure 3b, d).
Ganster et al. Critical Care 2010, 14:R165
http://ccforum.com/content/14/5/R165
Page 4 of 11
NaHS reduces I/R-induced up-regulation of cardiovascular
phosphorylated I-B and cell adhesion molecules in aorta
Compared to the HS-saline group, NaHS significantly
decreased P-IB and protein concentrations in the aorta
(Figure 4a) and heart (Figure 4e) whereas NF-B
decreased only in the heart (Figure 4d). In addition, HS-
NaHS treated rats showed a significant decrease in blot-
ting for I-CAM in aorta (Figure 4c) but not in heart (P <
0.05) in comparison to the HS-saline group (Figure 4f).
NaHS reduces I/R-induced oxidative stress
Compared to the HS-saline group, Nrf2 was increased in
aorta (P < 0.05) (Figure 5a) concomitant with a subse-
quent increase in HO-1 and HO-2 expressions (Figure
5b, c). However, NaHS did not decrease Nrf2, HO-1
and HO-2 (data not shown) in heart of the HS-NaHS
group. Finally, compared to the HS-saline group, NaHS
limited O2
- release in both tissues (P < 0.05) (Figure 5d,
e).
Discussion
In the present study, we report the beneficial effects of
NaHS as an H2S donor, prior to retransfusion, in a
rodent model of controlled hemorrhage. The key find-
ings were that a single i.v. NaHS bolus immediately
before retransfusion of shed blood (i) limited the I/R
induced-decrease in MAP and (ii) was associated with
reduced inflammatory and oxidative stress responses.
Although H2S is usually considered as an endogenous
vasodilatator, this effect nevertheless remains a matter
of debate. At low concentrations (10 to 100 μM H2S),
Ali et al. [15] found a vasoconstrictor effect of H2S on
rodent aorta, whereas Dombkovski [20] reported that
H2S was responsible for either vasodilatation or vaso-
constriction, according to species and organ require-
ments. Furthermore, data reported in the literature are
highly conflicting: indeed, Mok et al. [17] reported an
increase in MAP in unresuscitated HS treated with H2S
synthesis blockers (DL-propargylglycine and μ-cyanoala-
nine) whereas Morrison et al. [16], using an opposite
experimental approach, reported beneficial effects of
H2S on survival in rats submitted to lethal unresusci-
tated HS. In the present study, compared to the HS-sal-
ine group, a single i.v. bolus of NaHS produced a
substantial increase in MAP in hemorrhagic rats. All
rats were well oxygenated (PaO2 >100 mm Hg, data not
shown), an observation that was not reported in the stu-
dies by Mok et al. [17] and Morrison et al. [16].
The absence of a detrimental effect on stroke volume
has already been reported by others [11,21,22]. Herein,
heart rate was not altered in either group while carotid
blood flow was higher in the HS-NaHS group. Since
blood flow was decreased in HS-saline, this would sug-
gest a higher stroke volume in HS-NaHS treated rats,
although this conclusion could be challenged since car-
diac output was not directly measured in this study.
Table 1 Hemodynamic and acid-base measurements
Control saline group (n = 5) Control NaHS group (n = 5) HS saline group (n = 11) HS NaHS group (n = 11)
MAP (mmHg)
Baseline 145 ± 8 147 ± 16 146 ± 13 140 ± 12
Reperfusion 128 ± 18 128 ± 18 131 ± 16 135 ± 14
End experiment 119 ± 20 126 ± 8 65 ± 32§ 101 ± 16.5*§
HR (beat/min)
Baseline 414 ± 25 402 ± 55 406 ± 45 414 ± 40
Reperfusion 408 ± 34 408 ± 34 420 ± 43 398 ± 45
End experiment 414 ± 25 426 ± 33 429 ± 45 423 ± 57
CBF (ml/min)
Baseline 5.4 ± 1.1 5.5 ± 2.3 7.1 ± 2.7 7.2 ± 2.3
Reperfusion 4.8 ± 0.7 6.3 ± 3.5 6.5 ± 2.9 8.4 ± 3.5
End experiment 4.1 ± 1.4 7.1 ± 3.9 1.86 ± 1.6§ 4.4 ± 1.9*§
pH
Baseline 7.41 ± 0.04 7.40 ± 0.09 7.34 ± 0.05 7.35 ± 0.03
Reperfusion 7.42 ± 0.04 7.38 ± 0.08 7.23 ± 0.12 7.22 ± 0.10
End experiment 7.40 ± 0.08 7.41 ± 0.04 7.27 ± 0.11 7.34 ± 0.09*§
Base excess (mM)
Baseline 4.56 ± 1.55 3.76 ± 1.30 2.41 ± 1.69 2.98 ± 1.71
Reperfusion 4.96 ± 2.16 2.82 ± 1.79 -7.24 ± 6.7 -3.28 ± 3.24
End experiment 2.60 ± 1.86 2.14 ± 2.74 -7.61 ± 7.23 -2.17 ± 3.58*
MAP, mean arterial pressure; HR, heart rate; CBF, carotid blood flow.
* P < 0.05 vs. HS saline. §P < 0.05 vs. reperfusion.
Ganster et al. Critical Care 2010, 14:R165
http://ccforum.com/content/14/5/R165
Page 5 of 11
Nevertheless, this result is in agreement with improved
ejection fraction in a model of myocardial I/R injury [23].
In the present study, NaHS treatment limited the
metabolic acidosis induced by I/R. Simon et al. [21] also
reported similar metabolic effects in pigs. Whether this
effect is due to reduced metabolic demand induced by
the sulfide donor or to a direct effect on mitochondrial
K+ATP channels remains speculative since metabolic rate
was not measured.
It is well documented that cardiovascular dysfunction
during I/R is partly linked to the activation of the
NF-B/Rel pathway. This mechanism has been demon-
strated in recent investigations [24], allowing the expres-
sion of iNOS and subsequent overproduction of NO in
cardiovascular tissues [25]. As reported by others [26],
we show herein that NaHS induced an in vivo down-
expression of iNOs, with subsequent decrease in NO
overproduction.
Figure 2 Hemodynamic measurements. Mean arterial blood pressure (MAP) and carotid blood flow (CBF) in hemorrhagic shock (HS)/saline
group (white circle) and hemorrhagic shock/NaHS group (black circle) rats recorded during 300 minutes monitoring period. Data are expressed
as mean ± SD of n = 11 rats for HS/NaHS group, n = 11 rats for HS/saline group. *P < 0.05, significantly different between HS-saline and HS-
NaHS groups.
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The effects of H2S on inflammation are also a matter
of contention [25,27,28]. In the present model, we
report a predominant inflammatory modulation effect.
Indeed, NaHS was found to limit cardiovascular NF-B
activation as well as decrease I-CAM expression in
aorta. These results confirm in vitro experiments which
demonstrated that NaHS as well as other H2S endogen-
ous donors modulate leukocyte-mediated inflammation
[25,29] by decreasing leukocyte adhesion and leukocyte
infiltration [23] through activation of K+ATP channels
[25].
In the present study, infusion of a NaHS bolus attenu-
ated oxidative stress induced by I/R, as mirrored by a
decreased release of O2
- in tissues. H2S is known to
react with the four different reactive oxygen species
[30-32]. Since increased ROS formation is implicated in
lipid peroxidation and oxidation of thiol groups, H2S, by
decreasing ROS overproduction, may in fact limit tissue
damage. Our results show that O2
- production was
decreased in both aorta and heart, suggesting a protec-
tive effect on cardiovascular tissues. These results are in
agreement with the observations of Sivarajah et al. [33],
who recently reported that the cardioprotective effects
of NaHS in a model of I/R on isolated cardiomyocytes
were related to antioxidative and anti-nitrosative
properties.
Nrf2 could contribute to adaptive and cytoprotective
responses to various cell damages [31,34]. Different anti-
oxidant cellular pathways are associated with Nrf2
expression such as the heme oxygenase enzymes, HO-1
and HO-2. Indeed, Maines et al. [30] reported increased
levels of HO-1 in I/R injuries; moreover, HO-1 was
found to improve resistance to oxidative stress [32] and
modulate inflammatory response, particularly in hemor-
rhagic shock [35]. HO-2, meanwhile, is found in almost
all tissues and is known as a potential O2 sensor in
Figure 3 NaHS administration reduces NO production and iNOS expression in aorta and heart. (a, c) Quantification of the amplitude of
NO-Fe(DETC)2 signal in unit/weight (mg of the dried sample Amplitude/Wd, n = 10) in the aorta (a) and heart (c) of the two groups of rats. (b,
d) Western blots revealing iNOS expression in the in the whole lysate of aortas (n = 6) (b) and in hearts (n = 6) (d) of two groups of rats.
Densitometric analysis was used to calculate normalized protein ratio (protein to b-actin). Data are expressed as mean ± SD. *P < 0.05,
significantly different between HS-saline and HS-NaHS groups.
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addition to playing a role in the maintenance of vascular
tone [32]. Conversely to aortic tissues, there were no
changes in Nrf2, HO-1 or HO-2 in the heart samples.
In the present experimental design, rats were anesthe-
tized and warmed but not overheated for ethical reasons
in accordance with our animal care regulatory agency.
The metabolic rate was not measured. In the studies of
Blackstone et al. [10,11] and Morisson et al. [16], ani-
mals were awake. The difference between the two
experimental protocols does not exclude a metabolic
Figure 4 Effects of NaHS on inflammatory pathway signaling. (a, d) Western blots revealing NF-kB expression in the aorta (a) and in the
heart (d). (b, e) Western blots revealing P-IB expression in aorta (b) and in heart (e). (c, f) Western blots revealing I-CAM expression in aorta (c)
and in heart (f). Proteins are expressed in the whole lysate of aorta (n = 6) and heart (n = 6) from two groups of rats. Densitometric analysis was
used to calculate normalized protein ratio (protein to b-actin). Data are expressed as mean ± SD. *P < 0.05, significantly different between HS-
saline and HS-NaHS groups.
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effect in our experiments. However, since body tempera-
ture remained constant throughout the study period, the
putative effect of hypothermia did not significantly con-
tribute to the observed results, which are related to
reduced inflammatory and oxidative stress pathways.
Consequently, the beneficial effect of NaHS is unlikely
the result of a hibernation-like metabolic state of “sus-
pended animation” as reported previously [10,11,16,22].
The present observation, however, confirms other
studies in which H2S donors NaHS and Na2S protected
against ischemia reperfusion injury [23,33,36-41] and
burn injury [29] independently of core temperature.
Study limitations
The present study has several limitations. By design, in
order to mimic a realistic emergency clinical situation,
we used a single i.v. dose of NaHS. Indeed, given the
potential harmful effects of H2S on cytochrome c and
Figure 5 Effects of NaHS on antioxidant pathway. (a, b, c) Western blots revealing in aorta Nrf2 (a), HO-1 (b) and HO-2 (c) in the whole
lysate of aortas (n = 6). (d, e) Quantification of the amplitude of O2
--Fe(DETC)2 signal in unit/weight (mg of the dried sample Amplitude/Wd, n
= 10) in the aorta (d) and heart (e) of the two groups of rats. Data are expressed as mean ± SD. *P < 0.05 and **P < 0.01, significantly different
between HS-saline and HS-NaHS groups.
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the lack of data pertaining to the ideal target dose in the
literature, we chose to infuse a single bolus dose of H2S.
Since a dose-response study was not performed, it is
possible that we may have missed toxic or beneficial
potential effects of the hydrogen sulfide donor.
Moreover, we did not assess the effects of NaHS on
inflammation and oxidative stress in non hemorrhagic
rats since the injection of a single dose of 0.2 mg/kg of
NaHS did not alter mean arterial pressure or carotid
blood flow. The absence of vascular effects in non
hemorrhagic rats may be related to the low infused dose
or to the opposite effects of NaHS on isolated arteries.
NaHS has been reported to exert a contractile activity
mediated by the inhibition of nitric oxide and endothe-
lial-derived hyperpolarizing factor pathways as well as a
relaxation through both K+ATP channel-dependent and
-independent pathways. In addition, Kubo et al. [14]
reported only a very brief and reversible decrease in
MAP (100 seconds) after i.v. injection of NaHS at 28
μmol/kg, which is equal to 0.31 mg/kg, a value close to
the dose used in the present study. One could speculate
that the beneficial effects of NaHS are unveiled in I/R
situations when iNOS is up-regulated.
Conclusions
The present in vivo experimental study of I/R following
resuscitated hemorrhagic shock in rats demonstrates
that a single i.v. bolus of NaHS limited the decrease in
MAP during early reperfusion and down-regulated
NF-B, iNOS and I-CAM expressions. These anti-
inflammatory effects were associated with decreased NO
and O2
- production. Such beneficial effects of H2S
donors warrant further experimental studies.
Key messages
• The results of this in vivo experimental study
demonstrate that a single i.v. bolus of hydrogen sul-
fide (considered as the third gaseous transmitter)
donor, NaHS, prevented ischemia reperfusion (I/R)-
induced hemodynamic dysfunction in a model of
controlled hemorrhage in rats.
• NaHS reduced NO production and I/R-dependent
iNOS expression and improved metabolic
dysfunction.
• NaHS down-regulated NF-B, iNOS and I-CAM
expressions in this model.
• NaHS reduced I/R-induced oxidative stress.
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